Eli Lilly Pipeline Updates Support Valuation Case Beyond Injectable GLP 1s [Yahoo! Finance]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Yahoo! Finance
Eli Lilly (NYSE:LLY) received a positive regulatory opinion in Europe for Olumiant in adolescents with severe alopecia areata. The company announced successful Phase 3b results for combined use of Taltz and Zepbound in psoriasis patients with obesity. Eli Lilly reported significant progress for its oral GLP-1 candidate orforglipron versus Novo Nordisk's oral semaglutide in Phase 3 trials. Eli Lilly is adding fresh momentum outside its flagship injectable GLP-1 portfolio, with new data and regulatory progress across dermatology, obesity and oral diabetes treatments. The stock trades at $1,007.73, with a return of 11.4% over the past year and a gain over the past 5 years. These updates come as investors reassess the recent 6.7% year to date decline and shorter term pullback. For investors watching NYSE:LLY, these pipeline developments help clarify how much of the story extends beyond current GLP-1 products. The European opinion on Olumiant, the Taltz and Zepbound combination da
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- Lilly Employer Connect platform launches with over fifteen independent program administrators offering tailored obesity coverage options to expand access to patients [Yahoo! Finance]Yahoo! Finance
- Lilly launches employer-connect platform to broaden weight-loss drug access [Yahoo! Finance]Yahoo! Finance
- Eli Lilly launches program to help boost employer coverage of obesity drugs in U.S. [CNBC]CNBC
- Lilly Employer Connect platform launches with over fifteen independent program administrators offering tailored obesity coverage options to expand access to patientsPR Newswire
- Forget AI. This Biotech Stock's Taking Off Right Now [Yahoo! Finance]Yahoo! Finance
LLY
Earnings
- 2/4/26 - Beat
LLY
Sec Filings
- 2/19/26 - Form 4
- 2/18/26 - Form 4
- 2/18/26 - Form 4
- LLY's page on the SEC website